Weekend Unlimited Inc. (“Weekend” or the “Company”) (CSE:POT, FSE:0OS1, OTCQB:WKULF) a lifestyle cannabis company, announces that it is accelerating the launch of its branded edibles line to meet growing demand in Oklahoma and provides information regarding the safety of the vape cartridges used for the Company’s branded product line.
“Our sales team is getting a tremendous response from retailers in Oklahoma as we introduce the Company’s branded product line overall,” said Mr. Chris Backus, President and CEO of Weekend. “Our line of chocolates, gummies and hard candies is getting an especially strong reception. We believe that demand for edibles is increasing due to the overall product innovations and also as a result of the media attention regarding e-cigarettes.”
Weekend is ideally positioned with its model to be highly responsive to retail and consumer needs; the Company’s agility is a strength that allows it to produce and deliver branded products to market quickly in response to consumer desires.
- WKND! accelerating launch of branded edibles line in Oklahoma
- WKND! edibles to include three products containing 2.5mg, 5mg and 25mg THC to meet consumer demand:
- Thin chocolate bar with salt sprinkles (100mgs divided into four 25mg squares)
- Hard candies
- WKND! branded product development team is also working on an almond bar for future launch
“As it relates to consumer safety across our WKND! branded products, including vape cartridges, the Company is wholly committed to providing customers with safe, reliable and consistent experiences,” stated Chris Backus.
Weekend Unlimited is dedicated to developing and marketing the safest and highest quality products for its customers. Noting the rise of possible lung-related illnesses associated with the use of e-cigarettes, the Company is providing information to its shareholders, customers and business partners as to the safety and quality of WKND! branded vape products.
Safety and Quality Information regarding WKND! branded vape cartridges:
- WKND! branded vape products contain no vitamin E acetate, vegetable glycerin or propylene glycol*
- WKND! branded vape product’s hardware is made with the highest quality micro-porous glass, regarded to be the cleanest type of cartridge, soon to be patented
- WKND! branded vape product’s hardware is made in a GNP and ISO certified factory
- WKND! branded vape products are third-party lab-tested on a regular basis and passed analysis for the heavy metals screen, which is standard protocol and includes testing for cadmium, arsenic, lead and mercury
- WKND! branded vape products meet and exceed California requirements, which represent the highest standards for heavy metal testing in the industry
*Each batch of concentrate is tested for heavy metals, pesticides, potency, foreign materials and any other harmful substances that could impact the integrity of the product. In conjunction with stringent testing, WKND! branded vape products do not contain any artificial additives including vitamin E Acetate, propylene glycol, vegetable glycerin or artificial flavoring. All blends are made with distillate solely from cannabis and flavored with HTE (high terpene extract), which is derived from live resin made only from quality cannabis material.
For further information, please contact:
Mr. Chris Backus, President & CEO, Director
Telephone: 1(236) 317-2812 – Toll free 1(888) 556-9656
About Weekend Unlimited Inc.
Weekend Unlimited is a lifestyle-based recreational cannabis company. The Company is developing premium products designed to deliver life’s highs, anytime, anywhere. With a presence in both the U.S. and Canada – and a unique entertainment and education division (Weekend Live!), Weekend Unlimited is well-positioned to launch and scale the brands that will define recreational cannabis. Learn more at www.weekendunlimited.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management’s current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “predicts”, “intends”, “targets”, “aims”, “anticipates” or “believes” or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
Green Thumb Industries Inc. (Green Thumb) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise™ retail stores, today announced that its executive team will participate in the following conference in March 2021:
Needham 2 nd Annual Virtual Cannabis Conference, March 3, 2021: Management will participate in one-on-one meetings.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.